stocktrademan
3 년 전
BPMC buy 98.69
I decided to make a scan based on John Carter's TTM Squeeze indicator.
Here is the chart layout for Thinkorswim
http://tos.mx/wiwLksF
Here is the actual scanner that picked this stock
http://tos.mx/TPsL1CD
https://finance.yahoo.com/quote/BPMC/profile?p=BPMC
https://www.barchart.com/stocks/quotes/BPMC
https://finviz.com/quote.ashx?t=BPMC
https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=BPMC
https://stockcharts.com/c-sc/sc?chart=BPMC,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b
https://www.barchart.com/etfs-funds/quotes/BPMC/technical-chart?plot=CANDLE&volume=toBPMC&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=BPMC&grid=1&height=500&studyheight=100&timeframe=2%20Months
normal chart
log chart
normal chart
log chart
TFMG
4 년 전
Blueprint Medicines Corp.
Blueprint Medicines Corp . is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
protagonist12
10 년 전
CAMBRIDGE, Mass., April 29, 2015 /PRNewswire/ -- Blueprint Medicines today announced the pricing of its initial public offering of 8,145,834 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines granted the underwriters a 30-day option to purchase up to an additional 1,221,874 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on April 30, 2015 under the ticker symbol "BPMC."
Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers for the offering. JMP Securities is acting as a co-manager for the offering. Wedbush PacGrow is also acting as a co-manager for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on April 29, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com, and from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806, or by fax at (631) 254-7140.
Contact:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Media:
Beth Keshishian
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com
SOURCE Blueprint Medicines
http://www.prnewswire.com/news-releases/blueprint-medicines-announces-pricing-of-initial-public-offering-300074756.html
protagonist12
10 년 전
Blueprint Medicines (BPMC) expects to raise $115 million in an initial public offering (IPO) on Thursday, April 30th. The company will be issuing 7,200,000 shares at a price of $15.00-$17.00 per share.
Blueprint Medicines has a market cap of $398 million.
Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Blueprint Medicines provided the following description of their company for its IPO: “We are a biopharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Our approach is to systematically and reproducibly identify kinases that are drivers of genomically defined diseases and to craft drug candidates with therapeutic windows that provide significant and durable clinical responses to patients. This integrated biology and chemistry approach enables us to drug known kinases that have been difficult to inhibit selectively and also identify, characterize and drug novel kinase targets.”.
Blueprint Medicines was founded in 2008 and has 60 employees. The company is located at 215 First Street, Cambridge, MA 02142,, US and can be reached via phone at (617) 374-7580 or on the web at www.blueprintmedicines.com.
Hot Features
프리미엄
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Monksdream
2 월 전
ziggy7796
2 년 전
Frankestin
5 년 전
chmcnfunds
6 년 전
north40000
7 년 전
